MOLN(MOLN)
MOLN
ANALYST COVERAGE4 analysts
HOLD
▲ +242.1%upside to target
Key MetricsTTM
Market Cap$142.54M
Revenue TTM—
Net Income TTM—
Free Cash Flow—
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-66.2%
Return on Assets-66.3%
Debt / Equity—
Current Ratio9.42
EPS TTM—
PRICE
Prev Close
3.74
Open
3.71
Day Range3.66 – 3.99
3.66
3.99
52W Range3.41 – 5.36
3.41
5.36
20% of range
VOLUME & SIZE
Avg Volume
3.8K
FUNDAMENTALS
P/E Ratio
-1.9x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
TECHNICAL
RSI (14)
28
Oversold
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
PDividend Pay
In 97 days
Aug 26
MOLN News
About
No description available.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Patrick Amstutz
Country
Switzerland
Website
Daniel SteinerSenior Vice President of Targeted Radio Therapeutics
Martin SteegmaierChief Scientific Officer & Member of the Management Board
Michael PitznerExecutive VP of Partnering & General Counsel
Robert HendriksSenior VP of Finance & Member of Management Board
Seth D. LewisSenior Vice President of Investor Relations, Communications & Strategy
Renate GloggnerExecutive Vice President of People & Community and Member of Management Board
Michael Tobias StumppCo-Founder, Executive Vice President of Projects & Member of Management Board
Pamela A. TrailStrategic Consultant
Patrick AmstutzCo-Founder, Chief Executive Officer, Member of Management Board & Director
Philippe LegenneChief Medical Officer & Member of the Management Board
Alexander ZurcherChief Operating Officer & Member of Management Board